Globus Medical, Inc. $GMED Shares Sold by Leith Wheeler Investment Counsel Ltd.

Leith Wheeler Investment Counsel Ltd. cut its position in shares of Globus Medical, Inc. (NYSE:GMED) by 8.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 159,535 shares of the medical device company’s stock after selling 13,788 shares during the quarter. Globus Medical comprises 1.1% of Leith Wheeler Investment Counsel Ltd.’s portfolio, making the stock its 24th biggest position. Leith Wheeler Investment Counsel Ltd.’s holdings in Globus Medical were worth $13,746,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of GMED. WCM Investment Management LLC purchased a new position in shares of Globus Medical in the 1st quarter worth about $16,965,000. Dimensional Fund Advisors LP grew its holdings in shares of Globus Medical by 2.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock worth $152,474,000 after purchasing an additional 33,976 shares during the period. Parallel Advisors LLC increased its position in Globus Medical by 63.3% during the 1st quarter. Parallel Advisors LLC now owns 1,778 shares of the medical device company’s stock worth $153,000 after purchasing an additional 689 shares in the last quarter. KBC Group NV increased its position in Globus Medical by 0.6% during the 1st quarter. KBC Group NV now owns 73,824 shares of the medical device company’s stock worth $6,361,000 after purchasing an additional 417 shares in the last quarter. Finally, Precision Wealth Strategies LLC raised its holdings in Globus Medical by 49.9% in the first quarter. Precision Wealth Strategies LLC now owns 9,393 shares of the medical device company’s stock valued at $809,000 after buying an additional 3,128 shares during the period. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Globus Medical

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the transaction, the director owned 510,175 shares in the company, valued at $41,201,733. The trade was a 4.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 18.38% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on GMED shares. Zacks Research cut shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. BMO Capital Markets started coverage on shares of Globus Medical in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 target price on the stock. Needham & Company LLC raised their target price on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a report on Monday, July 13th. Finally, Wall Street Zen cut shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Globus Medical presently has an average rating of “Moderate Buy” and a consensus price target of $103.75.

Globus Medical Stock Down 1.0%

NYSE GMED opened at $76.23 on Tuesday. Globus Medical, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The business has a 50 day moving average price of $79.83 and a two-hundred day moving average price of $86.37. The stock has a market cap of $10.35 billion, a PE ratio of 17.73, a P/E/G ratio of 1.59 and a beta of 0.95.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The company had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same quarter last year, the firm posted $0.68 earnings per share. The business’s quarterly revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Sell-side analysts anticipate that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.